Survey of 102 paediatric haemophilia providers in 38 countries: views on FVIII inhibitor risk with emicizumab in previously untreated patients varied (13% higher, 41% equal, 32% lower); 53% of those with access offered concomitant regular FVIII.
Guidelinen = 102
van Stam et al. The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders